In humans, mutations in these peptidases were reported to have an impact on the development of several serious diseases including neuropsychiatric disorders [14,15,16], Friedreich’s ataxia (FRDA) [17], autosomal recessive spinocerebellar ataxia type 2 (SCAR2) [18], and type 2 diabetes (T2D) [19] (see Table 1 below). This evidence concerns the gene LAP3 and autosomal recessive spinocerebellar ataxia 2.